Researchers Posed as Clients and Called Every Licensed Oregon Psilocybin Center. The Screening Held Up
Researchers posed as prospective clients and called Oregon’s licensed psilocybin service centers with risk factors that should have stopped a careless operator. Published October 12, the first independent audit of this market found every center that answered screened them properly.
Supervised care is the expensive model to run and the one that holds up under scrutiny. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The study | A mystery shopper audit in Health Affairs Scholar, published October 12 |
| The test | Scripted calls describing depression plus a genuine contraindication risk |
| The result | Every center reached asked about psychiatric history, medications and risk |
| Take-home use | Not permitted by a single center |
| Medication safety | None advised stopping an antidepressant without a physician |
| The open problem | Median session $1,900, and no center accepts insurance |
They Called With Red Flags on Purpose
Three of the co-authors made the calls. This was not a general inquiry.
One caller described depression with a personal history of alcohol use disorder. Another described depression with a family history of psychosis.
Both profiles carry real risk. A family history of psychosis is among the clearest cautions in psychedelic screening. The callers were testing whether anyone would wave them through.
Nobody did.
Oregon licenses facilitators rather than requiring a medical clinician in the room. Critics have argued for years that this would produce loose gatekeeping.
These calls are the first independent test of that claim.
Every Center That Answered Screened Properly
All 15 centers reached followed state law. Every one asked about psychiatric history, current medications and contraindications before recommending anything.
The questions went past a formality. Centers asked about suicidal ideation and about interactions with psychoactive medications.
Nearly every center flagged medications that do not combine well with psilocybin. Not one told a caller to stop an antidepressant without speaking to a physician.
No center permitted unsupervised or take-home use. None of them behaved like a dispensary.
One researcher described thoughtful conversations in which the facilitator engaged the caller and tried to gather as much information as possible.
Both caller profiles were ones a commercially motivated operator might have been tempted to accept. Neither was turned into a sale on the phone.
Why This Kind of Study Carries Weight
Most compliance data is self-reported by the operator being assessed. A mystery shopper study measures behavior instead.
It captures what a center actually says to a stranger who calls, which is the only version a prospective patient ever experiences.
That makes this the strongest evidence yet that licensed supervision in this market is real rather than nominal.
It also lines up with the clinical picture. A cohort study that followed 346 Oregon clients found serious adverse reactions were uncommon.
What the Study Did Not Measure
Fifteen phone calls assess intake conversations, not what happens inside a session.
Oregon licenses 26 service centers. Four had closed before the calls began, and seven of the remaining 22 could not be reached by phone during the study window.
Unreachable is not the same as closed, and the paper does not claim otherwise. Small operators miss calls, and some do not answer unknown numbers.
The practical consequence is still worth naming. Centers doing this work well are easier to find when somebody picks up.
The Cost Problem Is a Coverage Problem
The median session cost $1,900. No center accepted insurance.
That is the whole revenue model. Cash, one session at a time, in a state that funds its program through fees on licensees.
It is also the clearest argument in this study, and it is an argument for the operators rather than against them.
Centers are meeting a demanding standard of care with no payer behind them. Clinical quality is not the constraint on this market. Reimbursement is.
That distinction matters for how this market gets regulated next. Rules written to fix a safety problem would be aimed at the wrong target.
That pressure surfaced in September, when Oregon withdrew a proposed fee increase after licensees said they would leave. This study shows the math behind that position.
What It Means for Clinics Elsewhere
Oregon is the longest running regulated psilocybin market in the country, and every other state is watching it.
New Mexico is standing up its own program, and the clinician facing permit remains pending. The same cost structure will apply there.
It also strengthens a point we have made before. A model that carries real supervision costs needs a payer relationship, which is part of why an approved psilocybin drug may launch through clinics that already bill insurers.
For ketamine practices, the lesson is the familiar one. Documented screening is an asset, as we set out in our list of 8 gaps that create malpractice exposure.
There is a practical read for any operator here. Screening rigor and commercial viability are being treated as a tradeoff in public debate, and this study suggests they are not.
Nothing in this data suggests that careful screening is what puts a center under. The pressure is coming from the price and the absence of a payer.
The Bottom Line
The question hanging over regulated psilocybin was whether licensed centers would screen seriously or sell sessions. Independent researchers went looking, and the centers screened seriously.
That is a real result for a young industry, and operators should say so.
The paper appears in Health Affairs Scholar, led by teams at the University of Missouri and Washington University in St. Louis, and is open on the publisher site.
Patients comparing supervised options can start with our directory of verified clinics.
This article is for informational purposes and is not medical or legal advice. Psilocybin remains a Schedule I substance under federal law.
